emic stroke. These trials may not have been blinded, but they were randomized and used death as a common outcome event, which cannot, of course, be affected by ascertainment bias. The nonrandomized studies of thrombolysis (which make up the majority of available reports in the literature) were included simply to highlight how unusable they are to obtain a true assessment of the effect of thrombolysis and also to show the totality of the evidence and how important it is to stop doing nonrandomized comparisons.
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With respect to large-scale trials of acute stroke treatment, it is important to remember that it has taken nearly 40 
Response
Fisher and Zipseri measured the urinary excretion of thromboxane (TX) B2, the nonenzymatic hydrolysis product of TXA2. This is thought to reflect primarily the intrarenal synthesis of TXA2 (see Reference 2 for a review). In contrast, we reported measurements of the urinary excretion of 11-dehydro-TXB2, which derives from enzymatic degradation of TXB2 through the il-dehydro-dehydrogenase pathway and is considered to reflect primarily the extrarenal (largely platelet) synthesis of TXA2.
With regard to the importance of gender, we found no statistically significant difference in thromboxane biosynthesis between men and women, the excretion rate being 356+963 (n=47) and
